Right to Try Act
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Right to Try Act
This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are authorized by state law and intended to treat terminally ill patients. Patients receiving these treatments must be certified by a physician as having exhausted all other treatment options and as being at greater risk from their medical condition than the treatment. The physician must explain the treatment to the patient, including that the treatment is experimental, and the patient, or the patient's legal representative, must acknowledge the explanation.
A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment.
The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment.
The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration (FDA); and (3) not be approved, licensed, or cleared for sale by the FDA.
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 2368: Right to Try Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-2368/
"H.R. 2368: Right to Try Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-2368/.
H.R. 2368, 115th Cong. (2026), https://openamerica.io/bill/115-HR-2368/.
[H.R. 2368: Right to Try Act](https://openamerica.io/bill/115-HR-2368/)